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Abstract
Background: Drug resistance in Plasmodium falciparum poses a major threat to malaria control.
Combination anti-malarial therapy, including artemisinins, has been advocated to improve efficacy
and limit the spread of resistance. The fixed combination of oral artemether-lumefantrine (AL) is
highly effective and well-tolerated. Artemisinin/naphtoquine (AN) is a fixed-dose ACT that has
recently become available in Africa.
The objectives of the study were to compare the efficacy and safety of AN and AL for the treatment
of uncomplicated falciparum malaria in a high transmission-intensity site in Ivory Coast.
Methods: We enrolled 122 participants aged 6 months or more with uncomplicated falciparum
malaria. Participants were randomized to receive either artemisinin/naphtoquine or artemether/
lumefantrine with variable dose according to their weight. Primary endpoints were the risks of
treatment failure within 28 days, either unadjusted or adjusted by genotyping to distinguish
recrudescence from new infection.
Results: Among 125 participants enrolled, 123 (98.4%) completed follow-up. Clinical evaluation of
the 123 participants showed that cumulative PCR-uncorrected cure rate on day 28 was 100% for
artemisinin/naphtoquine and 98.4% for artemether/lumefantrine. Both artemisinin-based
combinations effected rapid fever and parasite clearance.
Interpretation: These data suggest that Arco® could prove to be suitable for use as combination
antimalarial therapy. Meanwhile, pharmacokinetic studies and further efficacy assessment should be
conducted before its widespread use can be supported.
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Background
Malaria remains a leading cause of morbidity and mortal-
ity in African children [1]. The basis for malaria control
throughout sub-Saharan Africa is an appropriate case
management, focusing on prompt treatment with effec-
tive anti-malarial drugs [2]. Plasmodium falciparum resist-
ance to affordable anti-malarial drugs (chloroquine and
sulphadoxine-pyrimethamine) has reached high levels
and noticeably hampered malaria control efforts in the
region [3].
Artemisinin-based combination therapy (ACT) has
proved effectiveness against malaria in Asia and Africa
[4,5], and most countries in Africa have now changed
their national treatment policy to incorporate artemisi-
nin-based combination regimens as first-line treatment
for uncomplicated malaria [6].
Because artemisinin derivatives are now the first-line treat-
ment for multidrug-resistant falciparum malaria in many
tropical countries, appearance of artemisinin-resistant
Plasmodium falciparum would have serious implications.
The development of suitable combinations of an artemisi-
nin compound with a second drug is therefore a priority.
The choice of a suitable partner for the artemisinins has,
however, been problematic.
Candidates are being developed, including lumefantrine,
amodiaquine, mefloquine piperaquine, pyronaridine,
and naphthoquinone.
Naphtoquine is a member of the 4-aminoquinoline group
that includes chloroquine.
Detailed in vivo and in vitro data about naphtoquine are
not available apart from one study published in Chinese
which showed that naphtoquine is proved to be effective
and well tolerated. During this study, the average fever-
subsidence time and the parasite-clearance time of
naphtoquine at single 24-hour dosage of 1,000 mg were
longer than those of mefloquine and artesunate, the 28-
day curative ratio of naphtoquine was higher than that of
mefloquine and artesunate [7].
The fixed combination of artemether/lumefantrine (AL)
has been used as first-line treatment for uncomplicated
falciparum malaria in several African countries [8].
The safety of AL has been extensively reviewed [9] and sev-
eral trials in Africa and all of them, in both children and
adults, have demonstrated its efficacy [10,11]. AL exists as
a fixed tablet formulation and it has been registered in a
large number of countries under the names of Coartem®or
Riamet®. The fixed tablet formulation helps to overcome
problems of compliance associated with non-coformu-
lated combinations.
Artemisinin/naphtoquine is a fixed-dose ACT that has
recently become available in Africa. In the only published
study evaluating Naphtoquine, this drug was highly effi-
cacious with a good safety and tolerability profile.
However, the epidemiology of malaria and patterns of
antimalarial drug used are quite different in Africa than in
Asia [12,13].
To compare the performance of AN with Artemether/
lumefantrine in Ivory Coast, we conducted a randomized
clinical trial comparing efficacy and safety of AN and AL
for the treatment of uncomplicated falciparum malaria in
Anonkoua-koute, an area of extremely high transmission
intensity.
Methods
Study design and study site
The study was conducted from November 2006 to January
2007 at the end of the rainy season, in the primary health
care center of Anonkoua-kouté, 10 kms from Abidjan.
This health care center is located in a crowded sub-urban
area with holoendemic P. falciparum transmission.
This trial was a randomized single-blinded clinical trial.
Participants
Inclusion criteria were the following: (1) six months old
or more; (2) P. falciparum monoinfection with parasitae-
mia level of 2,000 – 200,000 asexual parasites/μl of
blood; (3) axillary temperature equal or over 37.5°C at
the time of enrolment or history of fever during the pre-
ceding 24 h; (4) no history of serious side effects to study
medications; (5) no evidence of concomitant febrile ill-
ness; (6) provision of written informed consent by the
participant or by a parent or guardian (for children).
Exclusion criteria were as follows: (1) symptoms and/or
signs of severe malaria; (2) any danger sign (persistent
vomiting; inability to sit, stand, drink or breastfeed; (3)
recent history of convulsions and/or lethargy or otherwise
impaired consciousness; (4) haemoglobin concentration
≤ 6 mg/dl; (5) serious underlying disease or known allergy
to the study drugs.
Participants were also excluded after randomization, if
they repeatedly vomited their first dose of study medica-
tions.
The sample size for the study was calculated based on the
assumptions that day 28 PCR-corrected cure rates for the
ACTs will not be less than 95%, and that the cure rate for
either AN or AL will not be less than 85%. At 95% confi-Malaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
Page 3 of 10
(page number not for citation purposes)
dence interval, 80% power, and a sample ratio of 1:1, the
required sample per arm was 49. Allowing for a dropout
rate of 10%, a minimum of 55 participants were to be
recruited for each arm of the study.
Treatments and randomization
Participants recruited into the study were allocated to two
treatment groups using a computer generated random list
based on a simple random selection procedure without
the use of blocking or stratification by an off-site investi-
gator.
Sequentially numbered, sealed envelopes containing the
treatment group assignments were prepared from the ran-
domization list.
The study clinical investigators assigned treatment num-
bers sequentially and a third party investigator who is an
appropriately qualified member of the study site, allo-
cated treatment by opening the envelope corresponding
to the treatment number. The randomization codes were
secured in a locked cabinet accessible only by the third
party. Participants were enrolled by the study physicians,
and treatments were assigned and administered by the
third party.
Only the third party was aware of treatment assignments.
All other study personnel, including the study physicians
and laboratory personnel involved in assessing outcomes,
were blinded to the treatment assignments. Participants
were not informed of their treatment regimen.
Study treatment was started on the day of randomization
(day 0) and completed by day 2 according to the combi-
nation received.
The study drug Arco® (AN) was provided in blister packs
by Kunming Pharmaceutical Corp. (China) The active
ingredients are artemisinin and naphtoquine. Each tablet
contains 125 mg of artemisinin and 50 mg of naphto-
quine.
The comparator drug Coartem® (AL) was provided by
Novartis SA (swiss) in blisters packs. The active ingredi-
ents are artemether 20 mg and lumefantrine 120 mg.
Administration of treatment was as described below.
The dosing for artemisinin/naphtoquine (AN) was 1/2
crushed tablet for participants weighing between 6 kg and
10 kg; one crushed tablet for participants weighing
between 10 and 15 kg; two crushed tablets for participants
weighing between 15 and 25 kg; three tablets for partici-
pants weighing between 25 and 35 kg, and four tablets for
participants whose weight was at least equal to 35 kg. All
tablets were given twice on a single day; the second dose
being given eight hours after the first dose.
For artemether/lumefantrine (AL), the dosing was 1
crushed tablet for participants weighing between 5 and 15
kg; two crushed tablets for participants weighing between
15 and 25 kg; three tablets for participants weighing
between 25 and 35 kg; four tablets for participants weigh-
ing between whose weight was at least equal to 35 kg. All
tablets were given twice a day for three days; the second
dose was given eight hours after the first one and the third
dose 24 hours after the first one or 16 hours after the sec-
ond one, the following doses given every 12 hours.
For AN, the morning doses were directly observed, while
the evening dose was given to the participants to be taken
at home. For AL, the morning doses were also directly
observed over the three days of treatment, while the
evening doses were given to participants to be taken at
home. The empty sachets were returned to the study site
as evidence of taking the drug. Paracetamol tablets (three
doses per day for two days) were provided, to be taken if
needed. Participants who were absent for follow-up were
visited at home on the same day.
All tablets were either swallowed whole or crashed with
water.
In the case a participant vomits the first dose (D0) within
30 minutes of drug administration; a repeat full dose was
given. If this participant also vomits this repeat dose or
any subsequent dosing, he was not re-dosed and was with-
drawn from the study. A participant who was withdrawn
due to vomiting received rescue medication according to
local practices.
Follow-up procedures
Enrolled participants were given an identity code and
were assigned to receive either artemisinin/naphtoquine
(125/50 mg tablet) twice on a single day (Day 0) or arte-
mether/lumefantrine (20/120 mg tablet) twice a day for
three days (Day 0, 1 and 2). At enrolment, we asked par-
ticipants, children's parents or guardians about prior anti-
malarial therapy, use of other medications, and presence
of common symptoms. Axillary temperature and weight
were recorded, and a physical examination was per-
formed. We also collected blood by fingerprick for thick
and thin blood smears, and for storage on filter paper for
PCR analysis.
Participants were recommended to return to study site for
follow-up visit on days 1, 2, 3, 7, 14, 21 and 28, and any
other day, if they felt ill. Follow-up evaluation consisted in
a standardized history and physical examination. If partic-
ipants did not return for follow-up, they were visited at
home.Malaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
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Participants were excluded after enrolment if any of the
following occurred: (1) use of antimalarial drugs outside
of the study protocol; (2) parasitaemia in the presence of
a concomitant febrile illness; (3) withdrawal of consent;
(4) loss to follow-up, (5) protocol violation, or (6) death
due to a non-malaria illness.
Outcome
Treatment outcomes were classified according to 2003
World Health Organization (WHO) guidelines as early
treatment failure (ETF: danger signs or complicated
malaria or failure to adequately respond to therapy days
0–3); late clinical failure (LCF: danger signs or compli-
cated malaria or fever and parasitemia on days 4–28 with-
out previously meeting criteria for ETF); late
parasitological failure (LPF: asymptomatic parasitemia on
day 28 without previously meeting criteria for ETF or
LCF); and adequate clinical and parasitological response
(ACPR: absence of parasitemia on day 28 without previ-
ously meeting criteria for ETF, LCF, or LPF) [WHO assess-
ment].
The overall rate of treatment failure (Total Treatment Fail-
ure TTF) was computed as if the participant had an ETF,
LCF or a LPF. Only parasitaemia confirmed by PCR as
recrudescence was considered a treatment failure. Partici-
pants were also considered treatment failures if they
received rescue treatment on or before day 28.
Adverse event
An adverse event is defined as any unfavourable and unin-
tended sign, symptom, syndrome, or illness that develops
or worsens during the period of observation in the study.
Clinically relevant abnormal results of diagnostic proce-
dures including abnormal laboratory findings which was
considered by the investigator to be detrimental was
recorded as adverse events whether or not they have a
causal relationship with the study drug.
All observed adverse events were monitored actively and
passively from the time the participant has taken one dose
of study treatment through last visit, and were recorded
on the Case Report Form (CRF) according to Good Clini-
cal Practice (GCP) and ICH guidelines.
Laboratory investigation
Thick and thin blood smears were prepared and stained in
10% Giemsa solution for 30 minutes. The smears were
read to 100 fields with quantification of P. falciparum asex-
ual parasitaemia on the thick smear. Parasites were enu-
merated using thick film, as described by Shute [14]. The
parasite density (per μl of blood) was calculated, assum-
ing a normal leucocyte level of 8,000/μl. The thin film was
used to speciate the parasites.
A total of 123 participants over 125 complied freely with the study protocol up to the time of a new malaria episode or follow- up day 28 and had adequate data for the analysis of the endpoints Figure 1
A total of 123 participants over 125 complied freely with the study protocol up to the time of a new malaria 
episode or follow-up day 28 and had adequate data for the analysis of the endpoints.
Artemisinine-naphtoquine
n=6 3
Complete treatment and
available for follow-up
day 28 (n = 62)
524 Patients screened
125 randomized
314 No malaria
75 low parasite density
10 patients non falciparum
1 Lost to follow up
Artemether-lumefantrine
n=6 2
Complete treatment and
available for follow-up
day 28 (n = 61)
1 ExcludedMalaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
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A smear was considered negative if no parasite were seen
after review of 100 high-power fields. We also assessed
gametocytemia from thick blood smears. Thin blood
smears were reviewed for non-falciparum infections. A sec-
ond microscopist, who was unaware of the results of the
first reading, re-read all slides. A third microscopist una-
ware of the first two readings resolved discrepant slides.
A complete blood count plus serum alanine aminotrans-
ferase (ALT), serum asparate aminotransferase, serum
total bilirubin and serum creatinine assessments were per-
formed on the total participants at baseline and seven
days after initiation of treatment. Tests were also per-
formed if clinically indicated or if a significant abnormal-
ity was detected on day 7. Molecular genotyping
techniques were used to distinguish recrudescence from
new infection for all participants failing therapy after day
7. Briefly, filter paper blood samples collected on the day
of enrolment and on the day of failure were analyzed for
polymorphisms in the genes for merozoite surface pro-
tein-1 (msp-1) and merozoite surface protein-2 (msp-2)
using nested-PCR as previously described [15].
Management of recrudescent infections
Participants with uncomplicated recrudescent infections
were re-treated with quinine, 24 mg/kg/day for 5 days.
However, their response to repeat therapy was not
assessed.
Statistical analysis
Data generated were recorded in a log book and individ-
ual participants case record files. Data were entered and
analysed with EPI-Info version 6.4. Analysis of treatment
outcome was per protocol, which only included partici-
pants with treatment outcomes. Frequencies were com-
pared by chi-squared tests and Fisher exact tests, and
continuous variables by Student's t-tests, Mann-Whitney
U-tests, analysis of variance or Kruskal-Wallis tests as
applicable.
All the clinical and laboratory data collected were sub-
jected to quality control. The study was carried out accord-
ing to standard operating procedures following the
guidelines of good clinical practice.
On day 2 all slides were negative in the two treatment groups Figure 2
On day 2 all slides were negative in the two treatment groups.
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Table 1: Demographic, clinical, and parasitological characteristics of participants on day of recruitment
Male/Female), range 27/35 29/32**
Mean weight (kg.), range 41.52 (11–77) 41.40 (10–82) **
GM parasite count (μl)a, range 10 186.13 (2000–102420) 11 081.8 (2000–99120) **
Mean haemoglobin (g/dl) 11.02 (6.56–14.7) 10.9 (7.4–15.9) **
AN (n = 62) AL (n = 61)
a Geometric mean parasite count
* p = 0.01 **p > 0.05Malaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
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Ethics
The study was approved by our Ethical Committee. This
work was conducted in compliance with ICH-GCP guide-
lines. Patient's informed consent was obtained according
to the ethical principles stated in the declaration of Hel-
sinki 2000 version (amended in Tokyo 2004), the appli-
cable guidelines for ICH-GCP. The applicable laws and
regulations of Ivory Coast Informed consent document
was used to explain the risks and benefits of study partic-
ipation to the participant if adults or parent or guardian of
children participants in simple terms before the partici-
pant was entered into the study. The informed consent
document contains a statement that the consent is freely
given, parent or guardian of the participant was aware of
the risks and benefits of entering the study, and the partic-
ipant is free to withdraw from the study at any time. Writ-
ten consent was provided by participant or parent or
guardian. If the participant or parent or guardian was una-
ble to write, witnessed consent was permitted.
Results
Trial profile
A total of 524 participants were screened for study eligibil-
ity and 125 who fulfilled the inclusion criteria were
enrolled in the study (63 in AN arm and 62 in AL arm).
All participants gave their written informed consent
before participating in the study.
A total of 123 participants over 125 complied freely with
the study protocol up to the time of a new malaria episode
or follow-up day 28 and had adequate data for the analy-
sis of the end-points (Figure 1).
Two participants were lost to follow-up: one child in the
AN group and one in the AL group. Table 1 shows the
baseline characteristics of the eligible participants. The
two treatment groups were comparable in all characteris-
tics.
Parasites and fever clearance
Data of participants proportion who achieved parasites
and fever clearance during the 3 days of treatment are pre-
sented in figures 2 and 3 respectively.
Table 2: Therapeutic response by treatment group 
(pcr-uncorrected)
Classification (day 28) AN (n = 62) AL (n = 61)
ETF 0 0
LCF 0 1 (1.6%)
LPF 0 0
ACPR 62 (100%) 60 (98.4%)
ETF = Early treatment failure LCF = Late clinical failure LPF = Late 
parasitological failure ACPR = Adequate Clinical and parasitological 
response. As shown in Table 2, the ACPR was 100% for AN and AL 
on day 14 after treatment. On day 28 cure rates were 100% (62 of 
62) and 98.4% (60 of 61) for participants receiving AN and AL, 
respectively. When the efficacy results were corrected for PCR 
results, an ACPR of 100% was observed with AL (61/61). This 
difference between treatment arms was not statistically significant (p 
> 0.05)
Proportion of participants without fever (Figure 3) was similar on days 2 and 3 (p > 0.05) Figure 3
Proportion of participants without fever (Figure 3) was similar on days 2 and 3 (p > 0.05).
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Day 1 slide negative results were observed for 44 (71%) of
62 AN-treated participants and 42 (68.9%) of 61 AL-
treated participants. On day 2 all slides were negative in
the two treatment groups (Figure 2).
Absence of fever (defined as a temperature of < 37.5°C)
on day 1 was found for 49 (79%) of 62 AN participants
and for 42 (68.9) of 61 AL participants.
Proportion of participants without fever (Figure 3) was
similar on days 2 and 3 (p > 0.05).
Gametocytes carriage
Gametocytes carriage was similarly low in both treatment
groups. At the time of presentation, gametocytes carriage
occurred in 3 of 62 participants in the AN group and 2 of
AL group.
On day 7 only 3 participants (2 in the AN group and 1 in
the AL group) had detectable gametocyte counts.
Among participants in whom gametocytes were found at
any time during follow-up, parasite densities were < 45
parasites/ul of whole blood, and all participants had neg-
ative results of testing for gametocytes by day 28.
Therapeutic response
Table 2 shows the results of the 28-day therapeutic effi-
cacy of the drugs. The number of evaluable participants
with adequate clinical and parasitological response
(ACPR) were 62 (100%) for AN and 60 (98.4%) for AL.
the difference in the cure rate of the two regimens was not
statistically significant (p > 0.05).
Late clinical failure was observed in one participant
(1.6%) that received AL but in none of those treated with
AN.
Adverse events
The most commonly reported and possibly drug-related
adverse events to both combination therapies were effects
on the gastrointestinal (abdominal pain, anorexia, nau-
sea, diarrhoea and late vomiting) and central nervous sys-
tem (dizziness) (Table 3).
No severe alterations in renal, haematologic or hepatic
function were observed with any of the drug combina-
tions under study. The transaminase increases observed
on day 7 did not exceed 2.5 × normal values. Only one
participant in the AL group presented with a slight
increase in creatinine levels without any serious clinical
signs (Table 4).
Table 3: Clinical adverse event in the two arms of the study
Adverse event Artemisinin/naphtoquine Artemether/lumefantrine
N = 62 % N = 61 %
Asthenia 1 1.6 1 1.6
Anorexia 3 4.8 1
Nausea 1 1.6 3 4.8
Vomitting 1 1.6 3 4.8
Diarrhoea 2 3.2 1 1.6
Dizziness 2 3.2 1 1.6
Abdominal pain 1 1.6 2 3.3
Pruritus 1 1.6 0 0
The most commonly reported and possibly drug-related adverse events to both combination therapies were effects on the gastrointestinal 
(abdominal pain, anorexia, nausea, diarrhoea and late vomiting) and central nervous system (dizziness)
ETF = Early treatment failure LCF = Late clinical failure LPF = Late parasitological failure ACPR = Adequate Clinical and parasitological response. As 
shown in Table 2, the ACPR was 100% for AN and AL on day 14 after treatment. On day 28 cure rates were 100% (62 of 62) and 98.4% (60 of 61) 
for participants receiving AN and AL, respectively. When the efficacy results were corrected for PCR results, an ACPR of 100% was observed with 
AL (61/61). This difference between treatment arms was not statistically significant (p > 0.05)Malaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
Page 8 of 10
(page number not for citation purposes)
Discussion
Artesunate-based combinations are currently being evalu-
ated to assess their role in developing new anti-malarial
drug policies for African countries. The key goal of ACT is
to enhance cure rates and delay development of parasite
resistance to component drugs [16]. Côte d'Ivoire has
opted for artesunate/amodiaquine (ASAQ) and AL respec-
tively as first-line and second-line treatment of uncompli-
cated  falciparum  malaria, whereas other countries have
primarily chosen AL. This study has shown rapid parasite
and fever clearance in participants treated with six-dose
regimen of AL and one day course of AN.
The combination of artemisinin and naphtoquine in the
form of Arco® was developed as an alternative to estab-
lished combinations, such as artemether/lumefantrine.
Our data show that Arco® was effective and well tolerated
by Ivorian children and adults with uncomplicated falci-
parum malaria. We recruited 125 participants, mostly chil-
dren (58.1% in AN arm and 52.5% in AL arm), and were
able to obtain validated 28-day follow-up data for 123
participants (98.4%). Recrudescence occurred within 28
days in 1 participant in artemether/lumefantrine group.
The present trial confirmed the efficacy of the six-dose reg-
imen of AL given over three days [17]. No severe side-
effects attributable to study medication were found during
the follow-up period in any of the treatment groups. These
data suggest that Arco could prove to be suitable for use as
combination antimalarial therapy.
However, despite the promise of AN there are substantial
limitations to this regimen, including one day treatment
(more rapid emergence of resistance), and the lack of
WHO prequalification or GMP certification.
In high transmission settings characteristic of much of
sub-Saharan Africa, children who are semi-immune gen-
erally need treatment for malaria several times a year,
effects of therapy on subsequent infections should also be
Table 4: Biological tolerance to the two ACTs on days 0 and 7
Day Artemisinine/naphtoquine Artemather/lumefantrine
Aneamia 0 29/60 23/60
(Hb < 11 g/d) 48.3% 38.3%
7 36/60 34
60% 56.7%
Craetinemia > 14 0 0/60 1/60
0% 1.7%
7 0/60 1/60
0% 1.7%
SGOT > 48 0 0/60 0/60
0% 0%
7 0/60 0/60
0% 0%
SGPT > 45 0 0/60 1/60
0% 1.7%
7 0/60 1/60
0% 1.7%Malaria Journal 2009, 8:148 http://www.malariajournal.com/content/8/1/148
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considered. Indeed, recurrent illnesses due to recrudes-
cence and those caused by new infections are clinically
Indistinguishable [18]. Therefore, the effects of treatment
on the overall risk of subsequent recurrent malaria might
be regarded as the most important outcome for compari-
son between potential anti-malarial regimens.
This study of drug efficacy have limited follow-up to 28
days, according to WHO recommendations, and thus
only the short-term effectiveness of drugs has been com-
pared. Therefore, such study may not identify important
differences between treatment regimens.
Rather, differences in effectiveness can be fully appreci-
ated only with longer-term follow-up (42 days).
Cost, access, and local efficacy, data are also fundamental
elements to consider before AN is implemented as policy.
Further studies are needed to estimate the long-term safety
and pharmacological action of this ACT. This will provide
more information for countries where the use of this drug
may be considered an option. Artemisinin derivatives in
combination with classical anti-malarial drugs, which are
still effective as monotherapy, represent, therefore, the
best options for the treatment of malaria in situations
where chloroquine resistance exists.
For malaria-control programmes to benefit fully from
effective anti-malarial drugs, their regimens should be
highly efficacious, of short duration, well-tolerated, and
cheap. An added bonus would be the propensity to reduce
transmission and limit the development of resistance, a
possibility that might be achieved with the artemisinin
derivatives. Governments, including Ivory Coast govern-
ment, are morally obliged to subsidize the cost of treat-
ment with ACTs to ensure the well-being of all;
particularly vulnerable groups such as children under five
years of age.
A major obstacle to this drug's widespread use is the lacks
of WHO prequalification or GMP certification.
Further clinical trials involved large number of partici-
pants and 42 days follow-up data with pharmacokinetic
studies should be conducted before its widespread use can
be supported.
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